Summit Therapeutics Inc. $(SMMT)$ has announced the issuance of inducement awards consisting of options to purchase up to 94,050 shares of common stock. These awards have been granted to nine new employees as part of their employment agreement with the company, in accordance with Nasdaq Listing Rule 5635(c)(4). Approved by the Company's Compensation Committee, the options have a ten-year term and an exercise price of $22.75 per share, reflecting the closing price on May 14, 2025. The options will vest in equal annual installments over four years and are subject to a stock option agreement to be signed by each recipient.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.